Therefore, to examine whether treating tumor cells with irinotecan upregulates other immune molecules implicated in CD8+ T cells activation, we analyzed MHC class I (H-2Dk) and PD-L1 expression on tumors in the early phase after treatment. Here, CD8A is linked to neoplasm.